Evidence map›Paper›PMID 40740999›Full record

SynthesisFrontiers in pharmacology2025

Polymorphisms in

Luiz Carlos da Costa-Junior, Daniely Regina Freitas-Alves, Amanda Melo Leite Leão, Hayra de Andrade Vieira Monteiro, Rita de Cássia Barbosa da Silva Tavares, Maria Claudia Rodrigues Moreira, Marília Berlofa Visacri, Teresa de Souza Fernandez, Paulo Caleb Júnior de Lima Santos

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luiz Carlos da Costa-JuniorPostgraduate Program in Medical Sciences, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
Daniely Regina Freitas-AlvesEscola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz (ENSP-FIOCRUZ), Rio de Janeiro, Brazil.
Amanda Melo Leite LeãoEscola de Ciências da Saúde, Universidade do Grande Rio (Unigranrio), Duque de Caxias, Brazil.
Hayra de Andrade Vieira MonteiroClinical Research Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Rita de Cássia Barbosa da Silva TavaresBone Marrow Transplant Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Maria Claudia Rodrigues MoreiraBone Marrow Transplant Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Marília Berlofa VisacriDepartament of Pharmacy, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo (FCF-USP), São Paulo, Brazil.
Teresa de Souza FernandezCytogenetic Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Paulo Caleb Júnior de Lima SantosPostgraduate Program in Medical Sciences, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This systematic review assessed the impact of Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024517094, PROSPERO, CRD42024599998.

Indexed as

ABCB1calcineurin inhibitorsCYP3A4CYP3A5hematopoietic cell transplantation

Identifiers

PMID40740999
PMCPMC12309307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.